$NTRA

Sheena Jonathan sold $29K of NTRA

Sheena Jonathan sold 109 shares of Natera, Inc. (NTRA) at $267.99 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Aug 6, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest disclosed fact is the director’s open-market sale of 109 shares at $267.9893 on 2026-08-03, totaling $29,210.83, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale, but the 10b5-1 structure and small dollar value reduce expected market impact.

03

What to watch

The filing does not indicate intent beyond the plan; without context on prior sales cadence or total insider holdings changes over time, the signal is weak.

Relevance 2/10Novelty 3/10Timing: Filed 2026-08-05 for a sale dated 2026-08-03.

Background

The article is a SEC Form 4 insider transaction disclosure for Natera, Inc. (NTRA).

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera director Sheena Jonathan sold 109 shares in an open-market transaction at $267.9893 on 2026-08-03 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone; any reaction is likely muted.

Evidence & confidence

The filing is a Form 4 insider sale, but it is explicitly tied to a pre-arranged 10b5-1 plan and the disclosed size is modest ($29.2K).

Market effects

No clear sector read-through from a single small 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal risk management or valuation concerns, which some traders may still monitor.

Key entities

  • Natera, Inc.

    Company whose director insider sale is disclosed on Form 4.

  • Sheena Jonathan

    Director who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Jim Cramer Calls Natera (NTRA) “a Promising Story”

Natera (NTRA) reported Q2 revenue of $752.8M, up 37.7% YoY, and raised its 2026 revenue forecast. Jim Cramer called it a promising precision medicine platform but advised waiting for a pullback due to valuation concerns. The company faces competition and regulatory risks, with a net loss of $67M in Q2.

$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.